Emerging evidence has demonstrated that KIAA1429-mediated m6A modification modulates the expression of multiple downstream targets including LINC01106, ARHGAP30, MAP3K2, MUC3A, KLF1, WTAP, HOXA1, RXFP1, BTG2, and DAPK3, which collectively drive NSCLC progression, metastasis, and the development of gefitinib resistance (Table 6). Here, VIRMA is linked to non-small cell lung carcinoma.